EGFR is known to be highly expressed in the majority of ovarian cancers, but phase II/III trials of EGFR inhibitors have not shown favorable clinical outcomes among unselected cohorts of ovarian cancer patients, or among any subgroups thus far identified [18, 40]. The gene discussed is EGFR; the disease is ovarian cancer.